COVID-19: Why did some people vaccinated against the virus develop dangerous forms of the disease?

This is undoubtedly the main goal of the vaccination campaigns being conducted today against Covid-19: protection against dangerous forms of the disease. During this pandemic, some people who completed the vaccination schedule unfortunately suffered from immunodeficiency. How is this possible?

Read also:
The seventh wave of COVID-19: What are the forecasts of the Pasteur Institute for the next few days?

An international study published last June begs the question. Published in the magazine Immunology Piloted by a team of French researchers, this study looked closely at 48 cases of severe forms of the disease in people who had completed their vaccination schedule. Inserm, the University of Paris Cité and the Imagine Institute recruited patients from Greece, France, Turkey, Macedonia, Ukraine and the United States. Here there are 34 men and 14 women, ranging in age from 20 to 86. The latter, all vaccinated against the virus, contracted the delta form of Covid-19. They were all transferred to the intensive care unit after infection.

Antibody Trail

To understand how these patients developed a severe form of the disease, the researchers first wanted to see if the vaccine had allowed these people to provoke an immune reaction. Objective: To ensure that the vaccine is working properly in these patients. Six patients were excluded from this study and for good reason: vaccination did not allow them to be supplied with neutralizing antibodies.

Read also:
Holidays and Covid-19: Spain, Portugal, Italy, Greece … What is the health situation in your summer destination?

However, the researchers found in the remaining 42 patients an antibody that targets specific molecules of our immune system: “type 1 interferon” (IFN-1). These antibodies are responsible for fighting the virus and which make it possible to stop its reproduction. 10 of the 42 patients examined had already developed ‘autoantibodies’ that prevent IFN-1 from working properly. These autoantibodies were present in these patients long before they contracted the virus.

Paul Bastard, one of the study’s signatories, explains to our colleagues from Globalism. In the absence of this first defense, the virus replicates very quickly. Antibodies to Covid-19 from vaccination arrive too late: they fail to neutralize the virus. Paul Bastard believes it would be useful to track these ‘autoantibodies’ in immunocompromised individuals: ‘Percentage of people with these autoantibodies’ autoantibodies increase dramatically with age: less than 1% among those without 65 years, and over 4% are between 80-85 years old”, concludes the researcher.